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ABSTRACT
Oncolytic adenovirus and apoptosis inducer TRAIL are promising cancer 
therapies. Their antitumor efficacy, when used as single agents, is limited. Oncolytic 
adenoviruses have low infection activity, and cancer cells develop resistance to 
TRAIL-induced apoptosis. Here, we explored combining prostate-restricted replication 
competent adenovirus-mediated TRAIL (PRRA-TRAIL) with lovastatin, a commonly 
used cholesterol-lowering drug, as a potential therapy for advanced prostate cancer 
(PCa). Lovastatin significantly enhanced the efficacy of PRRA-TRAIL by promoting 
the in vivo tumor suppression, and the in vitro cell killing and apoptosis induction, via 
integration of multiple molecular mechanisms. Lovastatin enhanced PRRA replication 
and virus-delivered transgene expression by increasing the expression levels of 
CAR and integrins, which are critical for adenovirus 5 binding and internalization. 
Lovastatin enhanced TRAIL-induced apoptosis by increasing death receptor DR4 
expression. These multiple effects of lovastatin on CAR, integrins and DR4 expression 
were closely associated with cholesterol-depletion in lipid rafts. These studies, for 
the first time, show correlations between cholesterol/lipid rafts, oncolytic adenovirus 
infection efficiency and the antitumor efficacy of TRAIL at the cellular level. This 
work enhances our understanding of the molecular mechanisms that support use of 
lovastatin, in combination with PRRA-TRAIL, as a candidate strategy to treat human 
refractory prostate cancer in the future.
INTRODUCTION
Prostate cancer (PCa) is the most commonly 
diagnosed, noncutaneous malignancy, and the second 
leading cause of cancer death, in males in the United 
States. Approximately 233,000 new diagnoses and 
29,480 deaths are predicted to occur in 2014 [1]. Patients 
frequently exhibit locally advanced disease and/or 
detectable distant bone metastases at initial presentation. 
Androgen ablation remains the main treatment modality 
recommended for patients with advanced disease, with 
an emerging role for chemotherapy. However, hormonal 
ablation is not curative. PCa inevitably progresses to an 
androgen-independent (AI) lethal phenotype over time. No 
curative therapy is available to treat PCa after it becomes 
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hormone refractory and metastasizes to bone. At this point, 
the disease becomes fatal.
Gene therapy is one option that holds promise to 
improve the targeted killing of hormone refractory PCa 
cells. For example, adenovirus 5 (Ad) vectors have a broad 
host range and can infect both normal and tumor cells [2, 
3]. To reduce unwanted side effects, it is important to 
develop oncolytic tissue and tumor-restricted, replication-
competent adenoviral vectors (TRRA). TRRA exhibit 
superior antitumor efficacy and safety when compared 
to replication-deficient Ad vectors, because TRRA 
actively propagates in and lyses the targeted cancer cells. 
In contrast, TRRA replication activity is low in normal 
cells. We developed a prostate-restricted, replication 
competent adenoviral vector (PRRA) by placing both 
adenoviral E1a and E4 genes under the control of a 
PSES enhancer to direct viral replication in a tissue and 
tumor-specific manner [4]. PSES is a chimeric prostate-
specific enhancer sequence, which combines the enhancer 
elements from PSA and PSMA genes, two well-studied 
prostate-specific biomarkers. PSES demonstrated high 
tumor specific activity in PSA/PSMA positive PCa cell 
lines [5]. PRRA showed prostate-restricted replication and 
killing activities in PSA/PSMA positive PCa cell lines [4]. 
However, the low virus infection efficiency and the limited 
virus distribution in the solid tumors limit the therapeutic 
potential of these oncolytic PRRAs for applications in 
prostate cancer. 
To improve therapeutic efficacy, we developed a 
series of gene-armed PRRAs by delivering suicide gene 
HSV-TK [6], apoptosis inducer TRAIL [7] and FasL [8], 
angiogenesis inhibitor endostatin and angiostatin fusion 
gene [9] and antitumor immune stimulator IL-12 [10]. 
The cancer-selective death-inducing character of TRAIL 
makes it an attractive candidate molecule for cancer 
therapy. TRAIL induces receptor-mediated apoptosis in a 
wide variety of cancer cell lines of diverse origin. TRAIL 
binding to death domain-controlled receptors, DR4 and 
DR5, triggers the death-inducing signal complex (DISC) 
formation and activation of procaspase-8, which in turn 
activates caspase-3, leading to cell death [11]. Normal 
cells can escape TRAIL-induced apoptosis through the 
expression of an antagonist decoy receptor, TRID [12]. A 
challenge to the in vivo use of TRAIL is that some cancer 
cells are resistant to TRAIL treatment. Many molecules 
in the TRAIL signaling pathway, including FLIPs, IAPs 
and IG20, can contribute to resistance mechanisms [13]. 
This means that high concentration of TRAIL protein is 
an essential prerequisite for this therapy to be viable [14]. 
We developed a TRAIL-expressing PRRA to improve 
delivery and targeting of TRAIL to tumor sites. PRRA-
TRAIL improved the antitumor efficacy of both PRRA 
and TRAIL by activating multiple molecular mechanisms 
[7]. Importantly, the PRRA-TRAIL virus-infected tumor 
cells produced soluble TRAIL, which triggered apoptosis 
of the surrounding cells uninfected by viruses [7]. 
An alternative strategy to increase tumor cell 
killing is to combine pharmaceutical agents with gene 
therapy. Pharmacologic agents that may be useful in 
this regard are the statins, 3-hydroxy-3-methylglutaryl 
(HMG) CoA reductase inhibitors, that are commonly 
used to lower cholesterol. Several large population-based 
epidemiological studies suggest that lovastatin reduced 
the risk of PCa [15-17]. Statins exert antitumor effects 
on PCa cell lines by inhibiting cell proliferation [18], 
interfering with the cell cycle [19] and inducing apoptosis 
[20]. Lovastatin molecular mechanisms include increased 
cytochrome c release, which reduced pro-caspase-3 
and increased activated caspase-3, independently of 
P53-induced apoptosis when combined with other 
chemotherapeutics, lovastatin exerts a synergistic effect 
to suppress tumor growth [21-23]. 
Here, we explored the consequences of combining 
lovastatin with PRRA-mediated TRAIL in proof-of-
principle experiments to support development of a 
novel strategy to treat refractory PCa. We determined 
the in vivo antitumor efficacy and extent of in vitro cell 
killing and apoptosis induction of PRRA-TRAIL and 
lovastatin therapy. Viral replication activity and transgene 
expression were assessed. Viral binding, internalization 
and intercellular trafficking were monitored after PCa cells 
were pre-treated with lovastatin. The levels of cholesterol/
lipid rafts on cellular membranes were assessed. Induction 
of apoptosis by either lovastatin or TRAIL alone or the 
combination of treatments was evaluated. The correlation 
of cancer cell apoptosis induced by lovastatin with 
the level of cholesterol/lipid rafts was analyzed. The 
expression of adenovirus-associated receptors CAR, 
selected integrins and the death receptors, DR4 and 
DR5, were assessed after lovastatin treatment. These 
studies add to our understanding of the role of membrane 
cholesterol in oncolytic adenovirus infection efficiency, 
and in induction of apoptosis by TRAIL. In summary, 
we identified key molecular mechanisms that support 
use of lovastatin in combination with PRRA-TRAIL as a 
candidate strategy to treat refractory PCa.
RESULTS 
Lovastatin significantly enhanced in vivo 
antitumor efficacy of oncolytic PRRA AdE4 and 
AdE4-TRAIL
In previous work, we developed a prostate-
restricted replication competent adenoviral (PRRA) 
vector AdE4PSESE1a (AdE4), in which both adenoviral 
E1a and E4 genes were controlled by PSES enhancer 
[4]. The adenoviral vector was used to deliver a series 
of therapeutic genes such as HSV-TK [6], TRAIL [7], 
FasL [8] and endostatin-angiostatin fusion genes [9] by 
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replacing EGFP gene with therapeutic genes (Figure 
1A) to improve antitumor efficacy. Here, we first tested 
if lovastatin improved the in vivo antitumor efficacy of 
AdE4 or AdE4-TRAIL in PSA/PSMA positive, androgen-
independent CWR22rv subcutaneous tumor xenografts 
in nude mice. In contrast to DMSO control, lovastatin 
alone, injected i.p. at 15 mg/kg/day, for 7 consecutive 
days, delayed the growth of tumor xenografts. Consistent 
with previous reports, AdE4 inhibited tumor growth, 
but only for the first 14 days after virus injection. After 
14 days, the tumors grew exponentially [4]. Lovastatin 
significantly enhanced the antitumor efficacy of AdE4. 
Average tumor size decreased by approximately 20% on 
day 21, and by 40% on day 28 (P<0.01). AdE4-TRAIL 
exhibited better antitumor efficacy than AdE4, due to 
incorporation of TRAIL (P<0.01). Interestingly, lovastatin 
greatly improved the antitumor efficacy of AdE4-TRAIL 
(P<0.01), because the tumor burden remained decreased 
for more than 14 days after virus injection (Figure 1B). 
On day 28, gross tumor size was much less in mice treated 
with lovastatin plus AdE4-TRAIL, than in those treated 
with AdE4-TRAIL alone (Figure 1B).
We harvested tumor xenografts at 28 days after 
cell incubation, and tested for adenovirus infection inside 
tumor tissues. No significant difference in adenovirus 
infection efficiency was observed between AdE4 and 
AdE4-TRAIL-treated tumors. When compared to control 
AdE4-infected tumors, lovastatin significantly increased 
AdE4 or AdE4-TRAIL viral-infection efficiency (P<0.01, 
Figure 1D). We also analyzed cell apoptosis inside tumor 
tissues by using an in situ fluorescent TUNEL assay. 
In contrast to DMSO control, lovastatin or AdE4 alone 
induced apoptosis in some cells. When combined with 
AdE4, lovastatin increased cell apoptosis (P<0.01). As 
predicted, AdE4-TRAIL induced more cell apoptosis 
than AdE4, due to the added apoptosis induction effect 
of TRAIL (P<0.01). Lovastatin further enhanced AdE4-
TRAIL-induced apoptosis (P<0.01, Figure 1E). These data 
suggest that lovastatin significantly enhances the oncolytic 
effect of replication competent adenoviruses, and may also 
enhance TRAIL-induced apoptosis.
Lovastatin enhanced in vitro cell killing and 
apoptosis induction by AdE4 and AdE4-TRAIL 
in PCa cells 
As lovastatin significantly enhanced in vivo 
antitumor efficacy of both AdE4 and AdE4-TRAIL, we 
tested if lovastatin would improve the in vitro killing 
effects of AdE4 and AdE4-TRAIL in PSA/PSMA-
positive PCa cells. CWR22rv or C4-2 cells were treated 
with either lovastatin, AdE4 or AdE4-TRAIL alone, or in 
combination. The doses of lovastatin and oncolytic viruses 
used in the combination experiments were determined in 
preliminary studies (data not shown). As shown in Figure 
2A, the control construct, AdE4(∆TATA)(100 vp/cell), 
did not exhibit detectable cell killing in CWR22rv cells, 
because the TATA box of E1a gene was deleted and the 
virus is replication-deficient (Figure 1a). Lovastatin (5 
μM) alone slightly increased cell killing, when compared 
to DMSO control (P<0.05). AdE4 (100 vp/cell) exhibited 
some cell killing activity because of the oncolytic effect 
of replication competent adenovirus. Lovastatin (5 μM) 
significantly increased the cell killing activity of AdE4 
(100 vp/cell) (P<0.01). Furthermore, AdE4-TRAIL 
exhibited more cell killing activity than AdE4 (P<0.01). 
Lovastatin further enhanced the cell killing activity of 
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Figure 1: Lovastatin significantly enhanced tumor suppression efficacy of oncolytic adenovirus constructs, AdE4 and 
AdE4-TRAIL. A. Structure diagram of prostate cancer-specific replicative adenovirus AdE4, AdE4-TRAIL, AdE4-Luc (AdE4 vector 
encoding a luciferase gene) and AdE4(∆TATA) (a replication-deficient adenovirus due to the deletion of TATA box of Ad E1a gene). B. 
CWR22rv xenografts were established in athymic nude mice. Mice were randomized 3 weeks after cell inoculation (8 mice/group, 1 tumor 
xenograft/ mouse). Tumors were treated with lovastatin at 15 mg/kg/day, i.p. for 7 consecutive days), or AdE4 (2 ×107 IFU in 100mL 
1×PBS i.t.), AdE4-TRAIL (2 ×107 IFU in 100mL 1×PBS i.t.), or lovastatin (i.p.) combined with AdE4 (i.t.), or lovastatin (i.p.) combined 
with AdE4-TRAIL (i.t.), for up to 28 days. Tumor size was measured on day 3 (D3), and then once every 7 days until 28 days (D28), and 
expressed as the average per group (n=8 xenografts/group),. C. Representative photographs of tumor xenografts (arrows) in 2 of the mice 
treated with AdE4-TRAIL (top) or lovastatin plus AdE4-TRAIL (bottom). On day 28, gross tumor size is much less in mice treated with 
lovastatin plus AdE4-TRAIL compared to those in mice treated with AdE4-TRAIL alone. D. Photomicrographs of immunohistochemistry 
of virus (Ad E1a) in tissue sections of xenografts after 28 days of treatment. The number of positive cells was counted in 10 randomly 
selected vision fields (original magnification: ×200) for each tissue section; the average of 3 tissue sections was used to represent each 
tumor. Lovastatin significantly enhanced virus infection inside tumor tissues (see graph below photomicrograph). E. Photomicrographs of 
tissue sections of xenografts showing fluorescence-labeled TUNEL+ apoptotic cells in tumor xenografts. The green fluorescent cells were 
counted in 10 randomly selected vision fields (original magnification: ×200) for each tissue section; the average of 3 tissue sections was 




Similar results were observed in C4-2 cells. The 
control, AdE4(∆TATA)( 50 vp/cell), did not exhibit 
detectable cell killing activity. Lovastatin (2.5 μM) alone 
induced a minor level of in vitro killing. AdE4 (50 vp/
cell) alone exhibited some cell killing activity, compared 
to DMSO control. Lovastatin (2.5 μM) significantly 
increased cell killing activity of AdE4 (50 vp/cell) 
(P<0.01). AdE4-TRAIL exhibited more cell killing activity 
than AdE4 (P<0.01), and lovastatin enhanced this even 
more when used with AdE4-TRAIL (P<0.01). Together, 
these in vitro results show that lovastatin significantly 
enhanced the cell killing activity of AdE4, and further 
enhanced cell killing induced by AdE4-TRAIL.
We tested the extent of apoptosis induced by 
lovastatin and adenovirus constructs in CWR22rv and 
C4-2 cells. Cells were treated with lovastatin for 16 hours, 
followed by virus infection for 24 hours. As shown in 
Figure 2B, in CWR22rv cells, AdE4(∆TATA)(100 vp/
cell) induced minor cell apoptosis (12.2%). Lovastatin (5 
μM) did not significantly affect AdE4(∆TATA)-induced 
apoptosis (16.3%). AdE4 (100 vp/cell) induced more 
cell apoptosis than AdE4(∆TATA) (25.1%). Lovastatin 
(5 μM) significantly increased AdE4 (100 vp/cell)-
induced cell apoptosis (43.6%) (P<0.01). AdE4-TRAIL 
exhibited a stronger apoptosis induction effect than 
AdE4 (40.2%, P<0.01); lovastatin further enhanced cell 
apoptosis of AdE4-TRAIL (62.4%, P<0.01). In C4-2 
cells, AdE4(∆TATA)(50 vp/cell) induced minor cell 
apoptosis (14.5%), while lovastatin (2.5 μM) did not 
significantly increase AdE4(∆TATA)-induced apoptosis 
(15.3%). AdE4 (50 vp/cell) induced more cell apoptosis 
than AdE4(∆TATA) (28.2%, P<0.01). Lovastatin (2.5 
μM) significantly increased AdE4 (50 vp/cell)-induced 
cell apoptosis (37.4%, P<0.01). AdE4-TRAIL exhibited a 
stronger apoptosis induction response than AdE4 (45.2%, 
P<0.01). Lovastatin further enhanced the cell apoptosis 
induced by AdE4-TRAIL (64.7%, P<0.01, Figure 2B). 
Figure 2: Lovastatin significantly enhanced induction of cell killing and apoptosis by AdE4 and AdE4-TRAIL. 
CWR22rv and C4-2 cells were treated with lovastatin (5μM for CWR22rv and 2.5μM for C4-2) for 16 hours, followed by virus infection 
of AdE4(∆TATA)(replication-deficient adenovirus), AdE4 or AdE4-TRAIL (100 vp/cell). A. The cells were stained with crystal violet, and 
the optical density was analyzed at OD490, at day 5 after virus infection. An index of relative cell killing activity for each treatment was 
calculated by comparing the treatment groups to control (PBS+DMSO). B. The percent of apoptotic cells was calculated at 48 hours after 
virus infection, as described in the Methods.
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Lovastatin significantly elevated viral 
transduction efficiency and AdE4-delivered 
transgene expression
In order to investigate the mechanism by which 
lovastatin enhances the in vivo antitumor effect of AdE4, 
in vitro cell killing and apoptosis induction, we first tested 
the effect of lovastatin on viral transduction efficiency and 
AdE4-delivered transgene expression. CWR22rv and C4-2 
cells were pre-treated with lovastatin, followed by AdE4 
infection for 24 hours. AdE4 vector encodes the EGFP 
gene, thereby allowing viral transduction efficiency to be 
assessed using flow cytometry to measure the percentage 
of green fluorescent cells. Compared to AdE4 alone, 
lovastatin increased the percent of green fluorescent cells 
by 23% or 27%, respectively, in CWR22rv or C4-2 cells 
(P<0.01, Figure 3A). To confirm this result, we infected 
the cells with AdE4-Luc, a PRRA vector expressing 
luciferase gene (Figure 1a). Luciferase activity was 
used as a measure of viral transduction efficiency, and 
measuring with a luminometer. Consistent with its effects 
in the AdE4 experiment, lovastatin significantly increased 
luciferase activity by 4~5-fold in both cell lines (P<0.01, 
Figure 3B). 
We also tested TRAIL protein expression after 
CWR22rv and C4-2 cells were pre-treated with lovastatin, 
and then infected with AdE4 or AdE4-TRAIL for 48 hours. 
TRAIL protein expression was detected by western blot. 
Lovastatin significantly increased AdE4-mediated TRAIL 
protein expression (Figure 3C). 
Lovastatin enhanced viral binding, internalization 
and trafficking to nuclei
The adenoviral infection pathway includes several 
critical steps: [1] Binding of adenovirus 5 capsid to cell 
receptor CAR. [2] Internalization by endocytosis through 
integrin αv, β1 and β3. [3] Lysis of the endosomal membrane, 
resulting in escape to the cytosol to facilitate trafficking 
along microtubules. [4] Binding to the nuclear envelop 
to enable insertion of the viral genome through nuclear 
pores. To test the impact of lovastatin on AdE4 binding, 
internalization and trafficking to nuclei, viral particles 
were continuously tracked after treating CWR22rv cells 
with lovastatin, and then infecting with AdE4 infection. 
The cells were incubated with adenoviral particles at 4ºC 
for 60 mins. After PBS washing, the amount of adenoviral 
particles was determined by assessing adenoviral E1a 
copy number, using quantitative PCR. Then, cells were 
incubated at 37ºC for another 30 minutes to allow time 
Figure 3: Lovastatin significantly enhanced AdE4-delivered transgene expression. CWR22rv and C4-2 cells were treated 
with vehicle (DMSO) or lovastatin at 10 μM for 16 hours. Then cells were infected with 100 vp/cell of AdE4 (A.) or AdE4-Luc (B.) or 
AdE4-TRAIL (C.) for the next 48 hours. AdE4-infected green fluorescent cells were monitored by FACS (A.); luciferase activity was 
measured by a luminometer (B.); TRAIL protein expression was assessed by western blotting (C.), all as described in Methods. 
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for virus internalization and trafficking to nuclei to 
occur. The attached but uninternalized viral particles 
were removed by subtisilin. Internalized adenoviral 
particles were analyzed for adenoviral E1a copy number 
by quantitative PCR assays. Nuclear DNA was prepared 
so that adenoviral E1a copy number inside nuclei could 
be analyzed by quantitative PCR. As shown in Figure 
4A, 4B and 4C, lovastatin significantly enhanced AdE4 
viral binding, internalization and trafficking to nuclei. 
Viral copy number increased by approximately 3.5-fold 
in the viral binding assay, by approximately 2.5-fold in 
the viral internalization assay, and by 1.6-fold in the assay 
to assess viral trafficking to nuclei. These results suggest 
that lovastatin significantly enhanced adenoviral binding, 
while exhibiting lesser effects on viral internalization 
and trafficking to nuclei. We speculate that the increased 
viral copy number in viral internalization and trafficking 
to nuclei can probably be attributed to the increased viral 
binding. 
To confirm that lovastatin enhanced viral trafficking 
to nuclei, we monitored viral particles inside the cells. The 
capsids of AdE4 first were chemically labeled with Alexa 
Fluor® 488 dye, prior to virus infection. The intracellular 
virions inside the cytoplasm and nuclei were assessed 
using an Amnis ImageStreamX cell analyzer. As shown 
in Figure 4D, at 30 minutes after allowing virus to bind 
at 37ºC, AdE4 viral particles were detected in cytoplasm, 
but few were detected inside the nuclei. Lovastatin 
significantly enhanced the adenovirus intracellular 
trafficking to nuclei, as most of the fluorescence in treated 
cells was detected inside the nuclei (Figure 4D). 
Figure 4: Lovastatin significantly enhanced adenoviral binding, internalization and intercellular trafficking to the 
nuclei. A. CWR22rv cells were treated with vehicle (DMSO) or lovastatin at 10 μM for 16 hours, then exposed to 5000 vp/cell of AdE4 
at 4ºC for 60 minutes. The unbound viral particles were removed; DNA of bound virus particles was processed for analysis of adenovirus 
E1a copy number by quantitative PCR assay. B. After viral binding, cells were allowed to internalize virus particles at 37ºC for other 30 
minutes. The attached but uninternalized viral particles were removed, and the DNA of internalized adenoviral particles for adenoviral E1a 
copy number using quantitative PCR. C. Nuclear DNA was separated, and adenovirus E1a copy number inside the nuclei was analyzed 
by quantitative PCR. D. Screen views of virus trafficking in individual cells, as monitored by the Amnis ImagestreamX cell analyzer. 
Adenoviral particles were labeled with Alexa Fluor® 488 dye. CWR22rv cells were treated with vehicle (DMSO) or lovastatin at 10 μM 
for 16 hours, and then exposed to virus at 5000 vp/cell of dye-labeled AdE4 for 60 minutes at 37ºC, to allow virus internalization; and then 
for 30 minutes, to allow for virus trafficking to the nuclei. Nuclei were stained with DAPI. Cells and viral particles were monitored using 
INSPIRE™ software, and the co-localization data of viral particles and nuclei were analyzed using IDEAS software. Three representative 
AdE4-treated single cells are shown in the left panel, and 3 representative AdE4 plus lovastatin-treated single cells are shown in the right 
panel. BF: brightfield showing the cell morphology; DAPI: nuclei; virus: dye-stained viral particles; DAPI/virus: co-localization of virus 
and nuclei showing viruses inside the nuclei; BF/virus: co-localization of virus and cell showing viruses inside cells. 
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Lovastatin increased the replication activity of 
AdE4
To test if lovastatin increases the replication activity 
of AdE4, we performed an adenovirus replication assay. 
As described in table 1, we pre-treated C4-2 or CWR22rv 
cells with lovastatin at 10 μM, and then infected cells 
with AdE4 at the dose of 6.6 × 104 virus particles in C4-2 
cells and 2 × 104 virus particles in CWR22rv (the virus 
doses used to infect cells were based on the relative virus 
infection efficiency of these two cell lines). The media 
were changed 6 hours after administering virus; 2 days 
later, supernatants were harvested to assess virus titer. 
The amount of adenovirus produced was expressed as 
TCID50. Lovastatin increased the virus titer from 2.5 × 
106 to 1.5 × 107 TCID50 in C4-2 cells and from 8 × 106 
to 2.5 × 107 TCID50 in CWR22rv cells. These data show 
that pre-treatment of lovastatin significantly promoted the 
replication activity of AdE4 in PSA/PSMA-positive cells.
Correlation of lovastatin-induced cell apoptosis 
with cholesterol level in lipid rafts on cell 
membranes
Non-malignant cells PZ-HPV-7 and MCF10A, and 
PCa cells C4-2, PC-3 and LNCaP cells were used to test 
the efficacy of lovastatin on cell apoptosis. Lovastatin 
(10 μM) selectively induced cell apoptosis in PCa cells, 
but not in non-malignant cells. We labeled lipid rafts on 
the cellular membrane with Alexa Fluo555/565-CTXB 
(GM), and labeled cholesterol with filipin (CH). The 
levels of lipid rafts and cholesterol on the membrane of 
PCa cells were much higher in PCa cells, than in non-
malignant cells. Lipid raft levels were highest in PC-3 
cells. Interestingly, the level of lipid rafts and cholesterol 
inversely correlated with the sensitivity of cells to 
lovastatin-induced apoptosis. We found that the higher 
the level of lipid rafts and cholesterol, the greater the 
magnitude of lovastatin-induced apoptosis (Figure 5A).
Because Lovastatin is a cholesterol-lowering drug, 
we tested the hypothesis that induction of apoptosis by 
lovastatin is via depletion of cholesterol in lipid rafts. 
We treated C4-2 cells with 10 μM lovastatin alone for 16 
hours, or with 500 μM cholesterol alone for 2 hours, or 
10 μM lovastatin for 16 hours, and followed by 500 μM 
cholesterol for 2 hours. Lovastatin significantly decreased 
cholesterol and lipid raft levels on cell membranes. In 
contrast, addition of cholesterol elevated the cholesterol 
level in lipid rafts. The lovastatin depletion of cholesterol 
and lipid rafts could be reversed by the addition of 
cholesterol (Figure 5B). The levels of cholesterol and lipid 
rafts on cell membranes closely correlated with apoptosis 
induction by lovastatin. In C4-2 cells, lovastatin (10 
μM) increased cell apoptosis from 9.8% to 32.4%, while 
cholesterol did not significantly alter cell apoptosis. The 
addition of cholesterol reduced lovastatin-induced cell 
apoptosis from 32.4% to 23.6%. Based on the correlation 
between induction of cell apoptosis by lovastatin and 
lowered levels of cholesterol and lipid rafts on the cell 
membranes, we speculate that the effect on apoptosis may 
be affected via depletion of cholesterol in the lipid rafts.
Lovastatin sensitizes PCa cells to TRAIL-induced 
apoptosis 
TNF-related apoptosis-inducing ligand (TRAIL) 
induces cell apoptosis by binding to the death receptors, 
DR4 and DR5 [11]. As shown in Figure 5C, A549, a 
lung adenocarcinoma cell line and Lovo, a colorectal 
cancer cell line exhibited high sensitivity to TRAIL-
induced apoptosis, while PC-3, a metastatic PCa cell line, 
showed some sensitivity to TRAIL-induced apoptosis. 
Other PCa cell lines, CWR22rv, LNCaP and C4-2, and 
non-malignant PZ-HPV-7 cells and keratinocytes were 
resistant to TRAIL-induced apoptosis (Figure 5C). In the 
PCa cell lines, LNCaP, C4-2 and PC-3, lovastatin (10 μM) 
or TRAIL(200 ng/mL) alone induced cell apoptosis. The 
percent apoptotic cells further increased when LNCaP, 
C4-2 and PC-3 cells were treated with a combination 
of lovastatin and TRAIL, but did not change in control 
PZ-HPV-7 cells or keratinocytes (Figure 5D). These data 
indicated that lovastatin selectively sensitized TRAIL-
induced apoptosis in cancer cells, but had no further effect 
in non-malignant cell lines.
Lovastatin increased expression of adenovirus 
binding receptors and TRAIL receptors in PCa 
cells
Adenovirus 5 infects cells by binding to CAR 
receptor, and internalizing into cells via the integrins [24]. 
The CAR receptors and integrins that bind adenovirus 
reside in cholesterol-enriched lipid rafts. Their expression 
is closely associated with the status of lipid rafts, and is 
affected by modification of lipid rafts [25-27]. Because 
lovastatin depletes cholesterol level and affects lipid rafts, 
we speculated that lovastatin might increase expression 
of CAR, integrin αv, β1and β3, to enhance AdE4 binding 
and internalization. We tested the effect of lovastatin on 
expression levels of CAR and integrins αv, β1 and β3 on the 
cell surface of CWR22rv and C4-2 cells, by either flow 
cytometry or western blot. As we hypothesized, lovastatin 
significantly increased the expression of CAR, consistent 
with increased adenovirus binding (Figure 6C). Lovastatin 
also slightly increased the expression of integrin β1 
and β3 (Figure 6A and 6B) and integrin αv (Figure 6C), 
consistent with enhanced virus internalization.. These 
data are consistent with our findings of changes in viral 
copy number after virus infection. Lovastatin enhanced 
adenoviral binding, internalization and viral trafficking to 
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nuclei (Figure 4A, 4B and 4C). These data suggest that 
lovastatin may enhance AdE4 infection efficiency and 
virus-delivered transgene levels, in part, by increasing 
the expression of adenovirus binding receptor CAR. 
Additional viral binding promotes viral internalization 
and trafficking to nuclei to increase virus replication and 
apoptotic cell death. 
We also assessed the effect of lovastatin on CAR 
expression in control non-malignant PZ-HPV-7 cells. 
Interestingly, lovastatin affected CAR expression 
differently in normal PZ-HPV-7, compared to the cancer 
cell lines. In CWR22rv and C4-2, which exhibit high 
cholesterol levels in lipid rafts, lovastatin increased 
CAR expression by depleting cholesterol in lipid rafts. 
In the non-malignant cell lines, such as PZ-HPV-7 that 
exhibit low cholesterol levels, lovastatin decreased CAR 
Figure 5: Lovastatin induced cell apoptosis, and sensitized cancer cells to TRAIL-induced apoptosis. A. Representative 
cells to enable visualization and overlays of lipid rafts/cholesterol in non-malignant and cancer cell lines, using confocal microscopy. 
Non-malignant cells PZ-HPV-7 and MCF10A and prostate cancer cells C4-2, PC-3 and LNCaP were labeled with Alexa red Fluo555/565 – 
CTXB (lipid rafts, glycolipoprotein microdomains, GM) and green filipin (cholesterol, CH) and analyzed by confocal microscopy. B. The 
correlation of level of lipid rafts/cholesterol and the sensitivity of cells to lovastatin-induced apoptosis. Serum-starved cells were treated 
with lovastatin at 10 μM or DSMO control for 16 hours, with triplicate-wells for each cell line. Apoptotic cells were stained with Annexin 
V-FITC and PI, and detected by flow cytometry. Data were expressed as the ratio of lovastatin-treated cells to control. C. The effect of 
lovastatin on the level of cholesterol in the lipid rafts and apoptosis in prostate cancer cells. Serum-starved cells were treated with DSMO 
(control) or lovastatin at 10 μM for 16 hours, and then incubated with or without 500 μM cholesterol for 2 hours. Cells were stained with 
CTXB-Alexa 555/558 (GM) and filipin (CH), and monitored by confocal microscopy. The cells were processed for Annexin V-FITC and PI 
staining, and the percent apoptotic cells analyzed by flow cytometry. Each experiment was replicated 3 times. D. Prostate cancer cells are 
resistant to TRAIL-induced apoptosis. Prostate cancer cells LNCap, C4-2, CWR22rv, PC-3, DU145, non-malignant prostate epithelial cells 
PZ-HPV-7, keratinocytes, non small lung adenocarcinoma cells A549 and colon cancer Lovo cells were treated with TRAIL protein for 24 
hours at a range of doses (n=5 for each cell line). Cell viability was measured by MTT assay at 72 hours after drug treatment. E. Lovastatin 
significantly enhanced TRAIL-induced apoptosis in prostate cancer cells, but not in normal cells. LNCaP, C4-2, PC-3, PZ-HPV-7 and 
keratinocytes were treated with lovastatin at 10 μM for 16 hours, before being treated with or without TRAIL(200 ng/mL) for 24 hours 
(n=4/group). The cells were processed for Annexin V-FITC and PI staining, and the percent apoptotic cells analyzed by flow cytometry. 
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Figure 6: A. to D. Lovastatin increased protein expression of selected cell receptors, which included CAR and integrin αv, β1 and β3, and 
TRAIL receptors DR4. CWR22rv, C4-2 or PZ-HPV-7 cells were treated with DSMO (control) or lovastatin at 10 μM for 16 hours. Protein 
expression of integrin β1 and β3 were determined in CWR22rv cells by flow cytometry (A, B); expression of CAR, integrin αν, DR4, DR5 
and cleaved caspase 3 were determined in CWR22rv and C4-2 cells by western blotting (C, D). Protein expression of CAR in PZ-HPV-7 
cells is shown in C. E. and F. Lovastatin significantly enhanced CAR and DR4 expression inside xenograft tumor tissues of mice after 28 
days of treatment. CAR and DR4 expression in tissue sections of xenografts were evaluated by immunohistochemical staining. The number 
of positive cells was counted in 10 randomly selected vision fields (×40) for each tissue section; 3 tissue sections were averaged to represent 
each tumor.
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expression (Figure 5A and Figure 6C). 
Previous studies demonstrated that death receptors, 
such as DR4 and DR5, are recruited into lipid rafts to 
facilitate protein-protein interactions and apoptosis 
induction [28]. Translocation of DR4/DR5 to lipid rafts 
promoted TRAIL-induced apoptosis [29]. When there is 
lower DR4/DR5 expression in lipid rafts, cells exhibit 
more resistance to TRAIL-induced apoptosis [28]. We 
hypothesized that, because lovastatin depleted cholesterol 
in the lipid rafts, lovastatin may sensitize cells to TRAIL-
induced apoptosis by regulating DR4 and DR5 expression. 
We tested the effect of lovastatin on DR4 and DR5 
expression at the cell surface of CWR22rv and C4-2 cells, 
using western blot. Lovastatin significantly increased DR4 
expression, but not DR5 expression, and induced caspase-
3-mediated apoptosis (Figure 6D). 
We tested the protein expression of CAR and DR4 
by using IHC staining of tumor tissues harvested during 
the in vivo studies. Lovastatin alone increased CAR 
expression compared to the DMSO control. Lovastatin 
significantly increased CAR expression inside tumor 
tissues when combined with AdE4 or AdE4-TRAIL, 
compared to either AdE4 or AdE4-TRAIL alone (Figure 
6E). These results from in vivo experiments confirm 
and extend our in vitro results. Lovastatin increased 
DR4 expression inside tumor tissues, compared to the 
DMSO control. Adenovirus infection slightly increased 
DR4 expression, while lovastatin combined with AdE4 
significantly increased DR4 expression inside tumor 
tissues (P<0.01). In contrast, AdE4-TRAIL decreased 
DR4 expression, probably because of the neutralization of 
DR4 by TRAIL ligand. DR4 expression also decreased in 
tumors treated with lovastatin and AdE4-TRAIL compared 
to those treated with lovastatin and AdE4 (Figure 6F). 
DISCUSSION
In the present report, we explored the efficacy 
of combining lovastatin with PRRA-mediated TRAIL 
in preclinical experiments, as a novel strategy to treat 
refractory PCa. The combination enhanced antitumor 
efficacy in vivo and in vitro through activation of multiple 
molecular mechanisms. Lovostatin enhanced the infection 
efficiency of PRRA and virus-delivered transgene 
expression by significantly increasing the expression 
level of CAR, and slightly increasing the expression of 
integrins. Lovastatin enhanced TRAIL-induced apoptosis 
by increasing the expression of death receptor DR4. 
Interestingly, these effects of lovastatin on CAR, integrins 
and DR4 expression levels were closely associated with 
lovastatin-depletion of cholesterol in lipid rafts of cellular 
membrane. 
Lipid raft microdomains reside in plasma membrane 
of cells, and they consist of dynamic assemblies of 
cholesterol [30]. Lipids localize to the exoplasmic leaflet 
of the membrane bilayer, while cholesterol is found in 
the inner leaflet [31]. Upon activation of key receptors by 
ligand binding, lipid rafts cluster into larger macrodomains. 
Various signaling molecules are recruited into these lipid 
raft macrodomains, to form the signaling platforms for 
transmembrane signal transduction [30-32]. Signaling 
molecules include those associated with virus infection 
signaling [33], apoptotic pathway signaling [34], death 
receptor activation signaling [32], and carcinogenesis 
[35]. Signal transduction can be affected by modifying the 
cholesterol content of lipid rafts. The level of cholesterol 
in lipid rafts was significantly higher in cancer cells than 
normal cells, and cholesterol accumulation enhanced 
cancer transformation and progression [36, 37]. Statins, 
such as lovastatin [38, 39] and simvastatin [37, 40], which 
inhibit the enzyme HMG-CoA reductase, catalyze a key 
rate-limiting step in cholesterol biosynthesis, and induce 
cell apoptosis by inhibiting PI3K/Akt signaling. 
The adenovirus 5 binding receptor, CAR, and 
integrins are found in cholesterol-enriched lipid rafts [25-
27]. Their expression is closely associated with the status 
of lipid rafts, such that modification of lipid rafts affects 
their expression [25-27]. CAR receptors and integrins, 
are critical for adenovirus 5 binding and internalization 
in cells. In the current study, lovastatin significantly 
increased the expression level of CAR, and slightly 
increased the expression levels of integrins through 
cholesterol-depletion in the lipid rafts of PCa cells. In 
contrast, lovastatin decreased CAR expression in non-
malignant cell lines with low cholesterol content. The 
results are consistent with the recent report that lovastatin 
decreased CAR expression in human normal umbilical 
vein endothelial cells (HUVEC) [41]. We speculate 
that the effect of lovastatin on CAR expression may 
be selectively governed by the availability and level of 
cholesterol in lipid rafts of cancer cells. 
Lipid rafts are closely associated with the activation 
of death receptors, such as DR4 [42], DR5 [42, 43] and 
FAS [44], depending on the cell model system. TRAIL-
induced apoptosis is associated with lipid raft formation 
and the status of death receptors inside the raft [45]. We 
report for the first time that induction of apoptosis by 
lovastatin correlated with the cholesterol level of lipid 
rafts, and that apoptosis induced by lovastatin in vitro can 
be mitigated by the addition of cholesterol. We speculate 
that, by increasing death receptor expression, lovastatin 
may overcome cancer cell resistance to TRAIL.
These studies, for the first time, demonstrate the 
correlations between cholesterol/lipid rafts and oncolytic 
adenovirus infection efficiency and antitumor efficacy of 
TRAIL in vitro. These findings add to our understanding 
of the molecular mechanisms that support the use of 
lovastatin, in combination with PRRA-TRAIL, as a novel 




In vivo animal studies 
A subcutaneous tumor xenograft model using 
the CWR22rv cell line was established as described 
previously [4]. Mice were inoculated with CWR22rv 
cells (1× 106 in 100 mL culture media) by subcutaneous 
injection. When tumor size reached ~5 mm in diameter at 
2-3 weeks after cell inoculation, the mice were randomly 
assigned to 6 groups. Three groups, received 10 mg/kg/
day of lovastatin in DMSO, and another 3 groups, served 
as controls, received PBS with the same dose of DMSO 
daily ip injections for 7 days. After the 7 day period, mice 
in each three groups individually received intratumor (i.t.) 
injections of 2×107 infectious unit (IFU) of AdE4PSESE1a 
(AdE4), AdE4-TRAIL or PBS control. To clarify, mice 
were sorted into the following groups (n=8 each group): 
[1] DMSO (i.p.), [2] lovastatin (i.p.), [3] AdE4PSESE1a 
(AdE4, i.t.), [4] AdE4-TRAIL (i.t.), [5] lovastatin (i.p.) 
with AdE4 (i.t.), and [6] lovastatin (i.p.) with AdE4-
TRAIL (i.t.). Tumor size was measured with calipers on 
days 3, 7, 14, 21 and 28, and tumor volume was calculated 
as length × width2 × 0.5236 [45]. Mice were sacrificed 
when tumor size exceeded 1000 mm3, or on day 28 if 
tumor size did not reach 1000 mm3. 
Histology, immunohistochemistry and in situ 
Terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) assay 
After mice were sacrificed, tumors were collected 
and immediately fixed in 10% phosphate buffered 
formalin, processed, embedded in paraffin and cut into 
5 um thin histological sections. To assess adenovirus 
infection, mouse monoclonal (SPM 230) antibody 
(ready for use) against adenovirus type 5 E1a (Abcam, 
Cambridge, MA, USA) and a super sensitive biotinylated 
second mouse antibody (BioGenex, San Francisco, CA, 
USA) were used. To assess expression of CAR and DR4 
protein, antibodies against CAR (H-300) or DR4 (C-20) 
(Santa Cruz Biotechnology. Santa Cruz, CA, USA) were 
used. Assessment of in situ apoptosis was performed with 
the TUNEL assay, using the manufacturer’s instructions 
(Roche Dianostics, Indianapolis, IN, USA). Positive-
staining cells were counted in 10 randomly selected vision 
fields (× 200) in each tissue slide. We counted cells in 3 
slides for each tumor. Results were expressed as mean ± 
standard deviation of 30 measurements/tumor. 
Cell lines and cell culture 
PSA/PSMA positive PCa cell lines LNCaP, C4-
2, CWR22rv and negative PCa cell lines PC3 and 
DU145 (ATCC, Manassas, VA, USA), were each 
maintained in RPMI-1640 medium, supplemented with 
10% FBS and 1% penicillin/streptomycin. Non small 
lung adenocarcinoma cell line, A549, and the Lovo 
colon cancer cell line (ATCC), were maintained in 
DMEM medium, supplemented with 10% FBS and 1% 
penicillin/streptomycin. Immortalized, non-malignant 
breast epithelial cell line, MCF10A, was maintained 
in the growth media as previously reported [46]. Non-
malignant, prostate epithelial cell line, PZ-HPV-7 (ATCC), 
and keratinocytes (Lonza, Anaheim, CA, USA) were 
maintained in KGM-Gold Bullet Kit (containing KBM-
Gold Basal Medium plus KGM-Gold SingleQuot Kit).
Cell Killing Assay 
C4-2 and CWR22rv cells were each seeded onto 
24-well plates (1 × 105/well), and treated with lovastatin 
(10 uM), AdE4(∆TATA)(replication-deficient adenovirus), 
AdE4 or AdE4-TRAIL at 100 virus particle (vp)/cell, or 
lovastatin (10 uM) for 16 hours, and followed by virus 
infection of AdE4(∆TATA), AdE4 or AdE4-TRAIL. Four 
wells were used for each treatment. All cells were stained 
with crystal violet dye at 5 days after virus infection, and 
lysed for OD read at 590 nm. 
Cell Viability Assay
 LNCap, C4-2, CWR22rv, PC-3, DU145, PZ-
HPV-7, keratinocytes, A549 and Lovo cells were each 
treated with TRAIL protein (R&D, Minneapolis, MN, 
USA) at a range of doses. Cell viability was measured by 
MTT assay 72 hours after drug treatment. 
Flow Cytometry Analysis to detect Cell Apoptosis 
CWR22rv and C4-2 cells were each seeded onto 
12-well plates (2.5 × 105/well), and treated with either 
vehicle control (DMSO), or 10 μM lovastatin, for 16 hours 
before infection with AdE4(∆TATA)(replication-deficient), 
AdE4 or AdE4-TRAIL, at 100 vp/cell (n=3 wells/group). 
Cells were harvested with 0.25% trypsin 48 hours post-
virus infection, and washed once with PBS preparatory 
to apoptosis detection. Serum-starved PZ-HPV-7 and 
MCF10A and C4-2, PC-3 and LNCaP cells were treated 
with 10 μM lovastatin for 24 hours, using triplicate-wells 
for each cell line. Serum-starved LNCaP cells were treated 
with or without 10 μM lovastatin for 16 hours, and then 
incubated with or without 500 μM cholesterol for 2 hours. 
LNCaP, C4-2, PC-3, and PZ-HPV-7 and keratinocytes 
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were treated with or without 10 μM lovastatin for 16 
hours, followed by the treatment of 200 ng/mL of TRAIL 
protein (R&D) for another 24 hours. Apoptotic cells were 
stained with Annexin V-FITC and PI, and detected by flow 
cytometry. 
Viral Replication Assay 
C4-2 and CWR22rv cells were seeded onto 6-well 
plates (1 × 106/well), and treated with 10 μM lovastatin 
for 16 hours. Then cells were infected with AdE4 at 6.6 
× 104 vp in C4-2 and 2 × 104 vp in CWR22rv cells to 
ensure equivalent viral infection efficiency. The doses for 
these cell lines were identified in preliminary experiments. 
The media were changed 6 hours after virus infection. The 
cells were harvested, and subjected to 3 freeze/thaw cycles 
48 hours post-virus infection. Virus soup was harvested, 
and titrated using virus titer assay described in previous 
publications, with the amount of produced adenovirus was 
expressed as TCID50 [4, 8].
Fluorescence Labeling of Cells for Lipid Raft and 
Cholesterol Detection 
Cells were grown on chamber slides (Nalgen Nunc 
International, Monroe County, NY, USA), and fixed in 
3% paraformaldehyde for 1 h at room temperature, before 
being incubated with 1 ml of 1.5 mg glycine/ml PBS for 
10 min at room temperature, to quench fluorescence due to 
paraformaldehyde. The cells were then labeled with Alexa 
Fluo555/565-CTXB (0.5 μg/ml, Molecular Probes of Life 
Technology, Grand Island, NY, USA) for 10 minutes on 
ice. After rinsing in PBS, the cells were incubated with 
1 ml of Filipin working solution (0.05 mg/ml in PBS, 
Sigma Aldrich, St. Louis, MO, USA) for 2 h at room 
temperature. Using confocal microscopy, glycolipoprotein 
microdomains (GM, lipid rafts) were viewed first, using 
a 543 nm laser, and then cholesterol was viewed, using a 
UV 350nm laser. 
Virus Binding and Intercellular Trafficking 
Detection by PCR Assays
The experiment protocol was developed according 
to Wang, et al’s report with modification [47]. Suspended 
CWR22rv cells were incubated with AdE4 (5000vp/cell) 
at 4 ºC, with vigorous shaking for 60 minutes, and the 
unbound viral particles were removed by washing cells in 
cold PBS 3 times. The DNA of bound virus particles was 
processed for analysis of adenovirus E1a copy number by 
quantitative PCR assay. After viral binding, virus particles 
were allowed to internalize and traffic to nuclei, at 37ºC 
for 30 minutes. To assess viral internalization, the attached 
but uninternalized viral particles were first removed using 
subtisilin (2 mg/mL, Sigma Aldrich), before assessing 
internalized adenoviral particles for adenoviral E1a copy 
number using quantitative PCR. Next, nuclear DNA was 
isolated using the NE-PER nuclear and cytoplasmic kit 
(Pierce Biotechnology, Ockford, IL, USA) adenovirus E1a 
copy number in the nuclei was analyzed by quantitative 
PCR assay. 
Virus Binding and Intercellular Trafficking 
Detection by Imagestream Cell Analyzer
AdE4 virus particles were labeled with Alexa 
Fluor® 488 dye. Next, suspended CWR22rv cells were 
incubated with AdE4 (5000 vp/cell) at 4 ºC, with vigorous 
shaking for 60 minutes [47]. Cells were then cultured at 
37 ºC for 30 minutes. After brief staining with DAPI, 
the cells were entered into the Amnis ImageStreamX cell 
analyzer (Amnis Corporation, Seattle, WA, USA) using 
low flow rate/high sensitivity settings, and evaluated 
using INSPIRE™ software. Amnis ImageStream Analyzer 
and IDEAS Analysis Software represent advances 
in multispectral imaging technology, because cell 
morphology and fluorescent labeling of genes or proteins 
can be simultaneously visualized in single cells. This 
powerful combination of quantitative image analysis and 
flow cytometry in a single platform creates exceptional 
new experimental capabilities [48]. The instrument and 
INSPIRE™ software were set up as follows: Channel 
1(DAPI); Channel 2 (virus, Alexa Fluor® 488); Channel 
3 (brightfield); and Channel 6 (scattering channel). 
Magnification was set at 60×, providing a pixel size of 
0.33 microns. The 405 nm and 488 nm lasers were used 
to activate multispectral fluorescence. The flow rate 
was set to low speed/high sensitivity; stream alignment 
was adjusted as necessary. The co-localization of virus 
and cellular nuclei, or virus and cells in brightfield was 
analyzed by IDEAS software. 
Preparation of Cells for Flow Cytometry Analyses 
to detect GFP Transgene Expression
CWR22rv and C4-2 cells were seeded onto 12-well 
plates (2.5 × 105 cells per well), and treated with 10 μM 
lovastatin for 16 hours before infection with AdE4 at 100 
vp/cell. DMSO-treated cells were used as the control. 
Cells were harvested using 0.25% trypsin 24 hours post-
infection, washed with FACS buffer (PBS with 5% FBS 
and 0.1% sodium azide) on ice, and then fixed in 0.5 ml 
of cold 1% paraformaldehyde solution. The GFP positive 
cells were analyzed.by flow cytometry.
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Bioluminescence analysis to detect luciferase 
transgene expression
CWR22rv and C4-2 cells were seeded onto 12-well 
plates (2.5 × 105 cells per well), and treated with 10μM 
lovastatin for 16 hours before being exposed to infection 
with AdE4-Luc (AdE4 vector encoding luciferase gene) 
at 100 vp/cell. DMSO-treated cells were used as the 
control. Cells were lysed 24 hours post-infection, and 
the cell luciferase activity was assessed with a Glomax 
luminometer (Promega, Madison, WI, USA). 
Western Blotting 
CWR22rv, C4-2 and PZ-HPV-7 cells were seeded 
onto 12-well plates (2.5 × 105 cells per well), and treated 
with 10 μM lovastatin for 16 hours before infection with 
AdE4 at 100 vp/cell. DMSO-treated cells were used as 
the control. Protein preparations (40 µg) were subjected 
to SDS-PAGE separation, and electroblotted to a 
nitrocellulose membrane. Antibodies against human CAR, 
integrin αυ, DR4, DR5 and caspase 3 were purchased 
from Santa Cruz Biotechnology. Primary antibodies were 
detected using horseradish peroxidase-conjugated anti-
rabbit IgG secondary antibody (Cell Signaling, Danvers, 
MA, USA). 
Detection of Integrin β1 and β3 Expression on 
Cells, Using Flow Cytometry 
CWR22rv cells were seeded onto 12-well plates 
(2.5 × 105/well), and treated with DMSO or lovastatin 
at 10μM for 16 hours. Cells were harvested using 0.25% 
trypsin, washed with FACS buffer on ice, re-suspended 
in 50 µl of buffer, and incubated on ice for 30 minutes 
with anti-human integrin β1 or β3 (R&D, Minneapolis, 
MN, USA), followed by washing three times. The cells 
were then incubated with a fluorescein-conjugated IgG 
secondary antibody (R&D) for 30 minutes, followed 
by 3 washes. Finally, cells were fixed in 0.5 ml of cold 
1% paraformaldehyde solution in preparation for flow 
cytometry analysis. The positive cells were analyzed in a 
histogram data. 
Statistical Analysis
The statistical comparisons of adenovirus 5 E1a, 
TUNEL, CAR and DR4 positive cells in the tissue 
sections, and in vitro cell killing activity, cell apoptosis, 
virus-mediated transgene expression, adenoviral binding, 
internalization and intercellular trafficking, TRAIL 
cytotoxicity between treatments were carried out by 
unpaired 2-tailed Student’s t test. In xenograft tumor 
studies, statistical analyses used one-way ANOVA to 
compare the tumor size among all treatment groups, and 
the pair-wise comparisons between treatment groups were 
adjusted with Bonferroni’s correlation. All data were 
presented as mean±SEM, and P value of less than 0.05 
were considered to be statistically significant for all tests. 
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